Oral Tolerance to Environmental Mycobacteria Interferes with Intradermal, but Not Pulmonary, Immunization against Tuberculosis

PLoS Pathogens

Volumn 12, Issue 5, 2016, Pages

  Price, Dominique N ^a,b   Kusewitt, Donna F ^c   Lino, Christopher A ^c,d   McBride, Amber A ^a,d   Muttil, Pavan ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d SANDIA NATIONAL LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD11B ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HERMES ANTIGEN; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BCG VACCINATION; BRONCHOALVEOLAR LAVAGE FLUID; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS REACTION; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; MYCOBACTERIUM AVIUM; NONHUMAN; REGULATORY T LYMPHOCYTE; TISSUE HOMOGENATE; TUBERCULOSIS; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; DISEASE MODEL; ENVIRONMENTAL EXPOSURE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LUNG TUBERCULOSIS;

ANIMALS; BCG VACCINE; DISEASE MODELS, ANIMAL; ENVIRONMENTAL EXPOSURE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; MICE; MICE, INBRED C57BL; MYCOBACTERIUM AVIUM; TUBERCULOSIS, PULMONARY;

EID: 84973333409     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005614     Document Type: Article

References (52)

1. World Health Organization (WHO)Global Tuberculosis Report 2015. 2016; 2–3.
2. World Health OrganizationGlobal tuberculosis report 2014 Geneva [Internet]. World Health Organization; 2014. Available: http://www.who.int/tb/publications/global_report/en/
3. Poyntz HC, Stylianou E, Griffiths KL, Marsay L, Checkley AM, McShane H, Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis. Tuberculosis (Edinb). 2014;94: 226–37. doi: 10.1016/j.tube.2013.12.006
4. Kamala T, Paramasivan CN, Herbert D, Venkatesan P, Prabhakar R, Isolation and Identification of Environmental Mycobacteria in the Mycobacterium bovis BCG Trial Area of South India. Appl Environ Microbiol. 1994;60: 2180–2183. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=201622&tool=pmcentrez&rendertype=abstract16349305
5. World Health OrganizationTrial of BCG vaccines in south India for tuberculosis prevention: first report *. Bull World Health Organ. 1979;57: 819–827. 396057
6. Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun. American Society for Microbiology (ASM); 2002;70: 672–8. Available: /pmc/articles/PMC127715/?report = abstract
7. Flaherty DK, Vesosky B, Beamer GL, Stromberg P, Turner J, Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination. 2006;
8. Demangel C, Garnier T, Rosenkrands I, Cole ST, Differential Effects of Prior Exposure to Environmental Mycobacteria on Vaccination with Mycobacterium bovis BCG or a Recombinant BCG Strain Expressing RD1 Antigens. Infect Immun. American Society for Microbiology; 2005;73: 2190–2196.
9. Young SL, Slobbe L, Wilson R, Buddle BM, de Lisle GW, Buchan GS, Environmental strains of Mycobacterium avium interfere with immune responses associated with Mycobacterium bovis BCG vaccination. Infect Immun. 2007;75: 2833–40. doi: 10.1128/IAI.01826-0617371857
10. Falkinham J, Pedley S., Bartram J, Environmental sources of Mycobacterium avium linked to routes of exposure. In: Pathogenic mycobacteria in water: a guide to public …. London: IWA Publishing; 2004. pp. 26–38. Available: http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Environmental+sources+of+Mycobacterium+avium+linked+to+routes+of+exposure#0
11. Falkinham JO, Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol. 2009;107: 356–67. doi: 10.1111/j.1365-2672.2009.04161.x19228258
12. Primm TP, Lucero CA, Falkinham JO, Health impacts of environmental mycobacteria. Clin Microbiol Rev. 2004;17: 98–106. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=321467&tool=pmcentrez&rendertype=abstract14726457
13. McShane H, Understanding BCG is the key to improving it. Clin Infect Dis. 2013;58: 481–482. doi: 10.1093/cid/cit79324336910
14. Ottenhoff THM, Kaufmann SHE, Vaccines against tuberculosis: where are we and where do we need to go?PLoS Pathog. 2012;8: e1002607. doi: 10.1371/journal.ppat.100260722589713
15. Weir RE, Black GF, Nazareth B, Floyd S, Stenson S, Stanley C, et al. The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guérin vaccination in southern England and northern Malawi. Clin Exp Immunol. 2006;146: 390–399. doi: 10.1111/j.1365-2249.2006.03222.x17100757
16. Belkaid Y, Naik S, Compartmentalized and systemic control of tissue immunity by commensals. Nat Immunol. 2013;14: 646–53. doi: 10.1038/ni.260423778791
17. Giri PK, Khuller GK, Is intranasal vaccination a feasible solution for tuberculosis?Expert Rev Vaccines. 2008;7: 1341–56. doi: 10.1586/14760584.7.9.134118980538
18. Ogra PL, Faden H, Welliver RC, Vaccination strategies for mucosal immune responses. Clin Microbiol Rev. 2001;14: 430–45. doi: 10.1128/CMR.14.2.430-445.200111292646
19. Holmgren J, Czerkinsky C, Mucosal immunity and vaccines. Nat Med. 2005;11: S45–53. doi: 10.1038/nm121315812489
20. Turner DL, Bickham KL, Thome JJ, Kim CY, D’Ovidio F, Wherry EJ, et al. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. 2014;7: 501–10. doi: 10.1038/mi.2013.6724064670
21. Jeyanathan M, Heriazon A, Xing Z, Airway luminal T cells: a newcomer on the stage of TB vaccination strategies. Trends Immunol. Elsevier Ltd; 2010;31: 247–52. doi: 10.1016/j.it.2010.05.002
22. Weiner HL, da Cunha AP, Quintana F, Wu H, Oral tolerance. Immunol Rev. 2011;241: 241–59. doi: 10.1111/j.1600-065X.2011.01017.x21488901
23. Strobel S, Mowat AM, Immune responses to dietary antigens: oral tolerance. Immunol Today. 1998;19: 173–181. doi: 10.1016/S0167-5699(97)01239-59577094
24. Tsuji NM, Kosaka A, Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol. 2008;29: 532–40. doi: 10.1016/j.it.2008.09.00218835746
25. Worbs T, Bode U, Yan S, Hoffmann MW, Hintzen G, Bernhardt G, et al. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J Exp Med. 2006;203: 519–27. doi: 10.1084/jem.2005201616533884
26. Shaler CR, Horvath C, Lai R, Xing Z, Understanding delayed T-cell priming, lung recruitment, and airway luminal T-cell responses in host defense against pulmonary tuberculosis. Clin Dev Immunol. 2012;2012: 628293. doi: 10.1155/2012/62829322545059
27. Jeyanathan M, Mu J, McCormick S, Damjanovic D, Small C-L, Shaler CR, et al. Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment. Am J Respir Crit Care Med. 2010;181: 862–72. doi: 10.1164/rccm.200910-1583OC20019338
28. Horvath CN, Shaler CR, Jeyanathan M, Zganiacz A, Xing Z, Mechanisms of delayed anti-tuberculosis protection in the lung of parenteral BCG-vaccinated hosts: a critical role of airway luminal T cells. Mucosal Immunol. Society for Mucosal Immunology; 2012;5: 420–31. doi: 10.1038/mi.2012.19
29. Xing Z, Importance of T-cell location rekindled: implication for tuberculosis vaccination strategies. Expert Rev Vaccines. 2009;8: 1465–8. doi: 10.1586/erv.09.11019863237
30. von Reyn C., Marlow J., Arbeit R., Barber T., Falkinham J, Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS. Lancet. 1994;343: 1137–1141. doi: 10.1016/S0140-6736(94)90239-97910236
31. Morris A, Reller LB, Salfinger M, Jackson K, Sievers A, Dwyer B, Mycobacteria in stool specimens: the nonvalue of smears for predicting culture results. J Clin Microbiol. 1993;31: 1385–7. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=262947&tool=pmcentrez&rendertype=abstract8501249
32. Belyakov IM, Ahlers JD, What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?J Immunol. American Association of Immunologists; 2009;183: 6883–92. doi: 10.4049/jimmunol.0901466
33. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. 2005;
34. Walrath J, Zukowski L, Krywiak A, Silver RF, Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis. Am J Respir Cell Mol Biol. 2005;33: 48–55. doi: 10.1165/rcmb.2005-0060OC15778493
35. Lagranderie MR, Balazuc a M, Deriaud E, Leclerc CD, Gheorghiu M, Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun. 1996;64: 1–9. 8557324
36. Kozak R, Behr MA, Divergence of immunologic and protective responses of different BCG strains in a murine model. Vaccine. Elsevier Ltd; 2011;29: 1519–1526. doi: 10.1016/j.vaccine.2010.12.012
37. Chen L, Wang J, Zganiacz A, Xing Z, Single Intranasal Mucosal Mycobacterium bovis BCG Vaccination Confers Improved Protection Compared to Subcutaneous Vaccination against Pulmonary Tuberculosis. Infect Immun. 2003;72: 238–246. doi: 10.1128/IAI.72.1.238-246.2004
38. Zwerling A, Pai M, The BCG world atlas: a new, open-access resource for clinicians and researchers. Expert Rev Anti Infect Ther. 2011;9: 559–61. doi: 10.1586/eri.11.7121819321
39. Demangel C, Garnier T, Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1. Infect Immun. 2005;73: 2190–2196. 15784562
40. Andersen P, Doherty TM, The success and failure of BCG—implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005;3: 656–62. doi: 10.1038/nrmicro121116012514
41. Palmer CE, Long MW, Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis. 1966;94: 553–68. Available: http://www.ncbi.nlm.nih.gov/pubmed/59242155924215
42. Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet. 2002;359: 1393–401. doi: 10.1016/S0140-6736(02)08353-811978337
43. Bermudez LE, Champsi J, Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immun. 1993;61: 3093–7. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=280968&tool=pmcentrez&rendertype=abstract8514420
44. Ho P, Wei X, Seah GT, Regulatory T cells induced by Mycobacterium chelonae sensitization influence murine responses to bacille Calmette-Guerin. J Leukoc Biol. 2010;88: 1073–1080. Available: http://www.ncbi.nlm.nih.gov/pubmed/20651297doi: 10.1189/jlb.080958220651297
45. Pinheiro RO, de Oliveira EB, Dos Santos G, Sperandio da Silva GM, de Andrade Silva BJ, Teles RMB, et al. Different immunosuppressive mechanisms in multi-drug-resistant tuberculosis and non-tuberculous mycobacteria patients. Clin Exp Immunol. 2013;171: 210–9. doi: 10.1111/cei.1200723286948
46. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, et al. Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis. J Immunol. American Association of Immunologists; 2004;173: 6357–6365. doi: 10.4049/jimmunol.173.10.6357
47. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO, Development of the human infant intestinal microbiota. PLoS Biol. 2007;5: e177. doi: 10.1371/journal.pbio.005017717594176
48. Valdez Y, Brown EM, Finlay BB, Influence of the microbiota on vaccine effectiveness. Trends Immunol. Elsevier; 2014;35: 526–537. doi: 10.1016/j.it.2014.07.003
49. Belkaid Y, Hand TW, Role of the microbiota in immunity and inflammation. Cell. Elsevier Inc.; 2014;157: 121–141. doi: 10.1016/j.cell.2014.03.011
50. Orme IM, Collins FM, Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Infect Immun. 1984;44: 28–32. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=263458&tool=pmcentrez&rendertype=abstract6423543
51. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet (London, England). 2013;381: 1021–8. doi: 10.1016/S0140-6736(13)60177-4
52. National Research Council (US) CommitteeGuide for the Care and Use of Laboratory Animals [Internet]. National Academies Press (US); 2011. Available: http://www.ncbi.nlm.nih.gov/books/NBK54050/